Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC): Competitive Landscape to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. This report provides an assessment of the pipeline, clinical, and commercial landscape of G/GEJAC.
Overall, GlobalData expects new drug approvals to drive G/GEJAC market growth over the next decade (2016–2026).
Scope
GlobalData’s Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC): Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the slide deck include:
• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type
• Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
• Commercial Assessment—leading marketed products, current and future players
• Competitive Landscape Analysis—key market events (2016–2026)
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global G/GEJAC market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global G/GEJAC market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Astellas
BeiGene
Boston Biomedical
Bristol-Myers Squibb
Celgene
Chi-Med
Daiichi
Eli Lilly
Five Prime
Gilead
Hengrui Medicine
Innomab
LSK BioPharma
Merck & Co
Merck KGaA
Roche
Sino
Sumitomo Dainippon
Taiho
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.